- Home
- IGR vs EBS Comparison
IGR vs EBS Comparison
Compare IGR & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGR | EBS |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.2M | 663.3M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | IGR | EBS |
|---|---|---|
| Price | $4.72 | $12.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 747.7K | ★ 978.2K |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 13.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $788,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.21 |
| P/E Ratio | ★ N/A | $8.82 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.88 | $4.02 |
| 52 Week High | $5.70 | $14.06 |
Technical Indicators
Market Signals| Indicator | IGR | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 60.12 | 52.36 |
| Support Level | $4.66 | $10.60 |
| Resistance Level | $4.83 | $12.58 |
| Average True Range (ATR) | 0.07 | 0.73 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 53.23 | 47.11 |
Price Performance
Historical ComparisonAbout IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.